CommercialCoverageMedium impact
Identification of Microorganisms Using Nucleic Acid Probes (2.04.10)
Blue Shield of California·CA · Infectious Disease, Family Medicine, Internal Medicine +4 more·Medical Policy
Effective date
Apr 1, 2026
We identified it
Dec 1, 2025
Summary
Blue Shield of California updated their nucleic acid probe testing policy effective April 1, 2026, defining which microorganisms are covered for direct/amplified probe testing versus investigational. The policy covers 32 specific microorganisms including COVID-19, flu, STDs, and respiratory pathogens, while limiting outpatient respiratory viral panels to 5 targets or less.
Action Required
By April 1, 2026: Billing team must review all nucleic acid probe test orders to ensure they match the covered microorganism list (32 specific organisms including SARS-CoV-2, influenza, chlamydia, etc.). Update prior authorization processes to require approval for investigational tests like CNS, GI, and urogenital pathogen panels. Limit outpatient respiratory viral panel orders to 5 targets or fewer - panels with 6+ targets will be denied. Train providers on the distinction between covered individual organism tests versus investigational multi-pathogen panels.